Immunome, Inc. (NASDAQ: IMNM) was founded in 2006 and is headquartered in Exton, Pennsylvania, USA, with 21 full-time employees. It is a biopharmaceutical company that uses the company’s proprietary human memory B cell platform to discover and develop first-class antibody therapies , Aims to change the current way of treating diseases.
Immunome, Inc. (IMNM):
Immunome is committed to developing first-class treatments, aiming to change our understanding and treatment of diseases.
Immunome was established to promote the discovery and development of new antibody-based drugs. Immunome’s proprietary antibody discovery platform uses B cells from patients with existing antibodies to identify novel therapeutic antibodies and their targets. By directly interrogating human B cells, Immunome can better understand how the body recognizes and overcomes diseases. In this way, the antibody discovery engine can quickly, accurately and effectively identify antibodies with the greatest potential to solve cancer and infectious diseases. This method can also enable Immunome to circumvent the weaknesses, complications and inefficiencies associated with conventional methods.
Immunome’s main focus is oncology (cancer), but the company’s technology may also find applications in new treatments for infectious diseases, including COVID-19.
The interleukin 38 targeted by Immunome’s leading discovery plan is a small protein that can be secreted by various cells in the body and seems to act as a new type of immune checkpoint inhibitor.
In July 2020, Immunome and the US Department of Defense reached an agreement to develop BCP product candidates that can potentially treat and prevent SARS-CoV-2 infections (including COVID-19). (BCP is an acronym for Biosynthetic Recovery Plasma.)
Immunome, Inc. (IMNM) investment:
Immunome, Inc. (NASDAQ: IMNM) was listed on NASDAQ on 10/2/2020 IPO. The issue price is $12.00, 2.5 million shares are issued, and 30 million U.S. dollars are raised. Ladenburg Thalmann/Chardan underwrites.